Results 341 to 350 of about 185,125 (388)

Management of Patients With Refractory Reflux-Like Symptoms Despite Proton Pump Inhibitor Therapy: Evidence-Based Consensus Statements. [PDF]

Aliment Pharmacol Ther
Armstrong D, Hungin AP, Kahrilas PJ, Sifrim D, Moayyedi P, Vaezi MF, Al-Awadhi S, Anvari S, Bell R, Delaney B, Emura F, Gyawali CP, Katelaris P, Lazarescu A, Lee YY, Repici A, Roman S, Rooker CT, Savarino EV, Sinclair P, Sugano K, Yadlapati R, Yuan Y, Zerbib F, Sharma P, International Working Group for the Classification of Oesophagitis (IWGCO).   +25 more
europepmc   +1 more source

Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonists

ESC Heart Failure, EarlyView.
Abstract Aims Data support favourable haemodynamic benefits of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on improving cardiac structural abnormalities and function in patients with heart failure (HF). However, the direct haemodynamic effects of GLP‐1 RAs remain inadequately characterized.
Haoran Jiang, Phuuwadith Wattanachayakul, Veraprapas Kittipibul, Erika Nicolsen, Todd McVeigh, Oksana Kamneva, Marat Fudim   +6 more
wiley   +1 more source

Predictors for the Development of Hypergastrinemia in Maintenance Treatment for Mild Gastroesophageal Reflux Disease Using a Half-dose Proton Pump Inhibitor. [PDF]

J Neurogastroenterol Motil
Jung DH, Youn YH, Jung HK, Lee KJ.
europepmc   +1 more source

Proton Pump Inhibitor use in Hospitalized Patients: Is Overutilization Becoming a Problem?

Clinical Medicine Insights: Gastroenterology, 2012
Cheryl Durand, Kristine C. Willett, Alicia R. Desilets   +2 more
doaj  

Bone health, renal outcomes, and iron deficiency anaemia in proton pump inhibitor versus histamine-2 receptor antagonist users: a retrospective cohort study based on TriNetX global collaborative network data. [PDF]

BMJ Open Gastroenterol
Chen TP, Wu MJ, Chen CH, Tsai SF.
europepmc   +1 more source

Appropriateness of Antiplatelet Therapy and Proton Pump Inhibitor Prescribing in End-Stage Kidney Disease: A Retrospective Quality Investigation Study. [PDF]

Can J Kidney Health Dis
Che M, Ahmed S, Chan R, Akbari A, Zimmerman D.   +4 more
europepmc   +1 more source

Effect of proton pump inhibitor (lansoprazole) on adverse drug reactions and rational drug use in elderly patients with chronic heart failure. [PDF]

Am J Transl Res
Zhou L, Kuang SQ, Lv Y, Yu WM, Wei XB, Lin S.   +5 more
europepmc   +1 more source

The Cost Effectiveness of Adjunctive Treatments for Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. [PDF]

Clin Drug Investig
Rosas US, Almario CV, Yu KS, Spiegel BMR.   +3 more
europepmc   +1 more source

Tegoprazan-Containing Versus Proton Pump Inhibitor-Containing Therapy for First-Line Eradication of <i>Helicobacter pylori</i>: A Meta-Analysis of Randomized Controlled Trials. [PDF]

JGH Open
Simadibrata DM, Lesmana E, Damara I, Izzatullah M, Danpanichkul P, Yoo HW, Hong SJ, Syam AF.   +7 more
europepmc   +1 more source

Influence of novel CYP2C-haplotype on proton pump inhibitor pharmacokinetics in children. [PDF]

Clin Transl Sci
Kyler KE, Gaedigk A, Abdel-Rahman S, Staggs VS, Pearce RE, Toren P, Leeder JS, Shakhnovich V.   +7 more
europepmc   +1 more source